All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation.
This is a retrospective and prospective, observational mixed-methods (quantitative and qualitative) cohort study of patients who are treated with either Ofatumumab or Ocrelizumab that will be recruited and followed up for one year to collect their profiles across the Gulf countries.
Relapsing Multiple Sclerosis
Jul 26, 2022
Jul 30, 2024
18 Years - 100 Years (Adult, Older Adult)
There is no treatment allocation. Patients administered Ofatumumab by prescription will be enrolled.
There is no treatment allocation. Patients administered Ocrelizumab by prescription will be enrolled.
Males and Females.
Age 18 to 65 years.
Confirmed RMS diagnosis as per the 2017 updated McDonald's criteria (Thompson et al., 2018).
Having their first dose of either drugs during the index period (2019 onwards and up to 1 year since start of the active recruitment period).
The decision to initiate either drug should be based on the patient's disease and taken by the treating physician before the decision of inviting the patient to participate in the study.
The patient agreed and provided informed consent on the use of his/her de-identified data.
Patients below 18 years or above 65 years.
SPMS and/or PPMS patients.
The patient's refusal to be included in the study.